this article has been archived; content may be out of date.
Customer is King: producing products that patients want
|24th July 2014
Harry Crook, from HA Crook Pharmacy Limited, talks about the importance of providing a patient-centric experience. Pharma companies should be producing products that patients want, because the patient is the most important thing. If, as a company, you don’t do it right then they go somewhere else!
In the booklet 'Customer Experience: The Essential Guide for Pharma', we mention that the customer isn't as concerned about the pharmaceutical company as they are about the drugs they make. Harry Crook agrees:
Pharmaceutical companies provide people like Harry Crook with a tool - the drug. It’s then their responsibility to give the patient a truly patient-centric experience with that product. At Blue Latitude Health, we know what it means to look at the patient journey from the patient's perspective. Behaviour changes from pre-diagnosis, diagnosis, treatment and recovery to the management of their condition. This affects their choices, decisions, and attitudes towards a service or product; as laid out in our Patient Information Journey poster.
Read more about human-centred design and customer engagement in our second issue of Perspective magazine.
Delivering impactful customer engagements in COVID-19
|14th July 2020
Blue Latitude Health, and our parent company Fishawack Health, have developed exclusive intellectual property, processes and tools to ensure you’re engaging customers in the right way. View our service one-pagers below to find out how we can help solve your challenges whether you’re in a medical, brand, portfolio or an above brand role.
Top 5 tips for a multi-indication product launch
|8th July 2020
Senior Associate Consultant Sana Rahim and Senior Consultant Victoria Clark explain the lessons the team has learned from launching six different indications of an oncology product in an accelerated timeframe.
If our patients are diverse, why are clinical trials so white?
|22nd June 2020
Despite facing worse health outcomes, minority populations are often left out of clinical trials and miss the opportunity to participate in life-saving research. Associate Consultant Ling Song explores this issue and calls for the pharmaceutical industry to change its approach.